Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects

Simple Summary: Nilotinib and other tyrosine kinase inhibitors (TKIs) target the BCR-ABL1 oncoprotein in Chronic Myeloid Leukemia (CML), reducing the growth of leukemic stem cells (LSCs) and promoting their death. However, some LSCs persist in the bone marrow (BM), which may lead to relapse and dise...

Descripción completa

Detalles Bibliográficos

Publicado en:	Cancers Vol. 17; no. 6; pp. 1022 - 1036
Autores principales:	Trojani, Alessandra, Pungolino, Ester, Di Camillo, Barbara, Bossi, Luca Emanuele, Palumbo, Cassandra, D'adda, Mariella, Perego, Alessandra, Turrini, Mauro, Elena, Chiara, Borin, Lorenza Maria, Iurlo, Alessandra, Malato, Simona, Spina, Francesco, Latargia, Maria Luisa, Spedini, Pierangelo, Artale, Salvatore, Anghilieri, Michela, Carraro, Maria Cristina, Bucelli, Cristina, Beghini, Alessandro
Formato:	research tables/charts Journal Article
Publicado:	MDPI Mar2025
Acceso en línea:	Ver este registro en EBSCOhost